市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | BeiGene, Ltd. | 混合的 | 混合的 |
AIStockmoo 评分
0.6
| 分析师共识 | 2.0 |
| 内部交易活动 | NA |
| 价格波动 | 3.0 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | 0.0 |
| 平均 | 0.63 |
|
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2023, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 50% of BeiGene’s revenue. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Large Growth |
| 内部持股比例 | 17.79% |
| 机构持股比例 | 44.98% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合